90. Giavedoni P., Ririe M., Carrera C., Puig S., Malvehy J. Familial Melanoma Associated with Li-Fraumeni Syndrome and Atypical Mole Syndrome: Total-body Digital Photography, Dermoscopy and Confocal Microscopy // Acta Derm Venereol. ‒ 2017. ‒ T. 97, № 6. ‒ C. 720-723.
91. Kittler H., Guitera P., Riedl E., Avramidis M., Teban L., Fiebiger M., Weger R. A., Dawid M., Menzies S. Identification of clinically featureless incipient melanoma using sequential dermoscopy imaging // Arch Dermatol. ‒ 2006. ‒ T. 142, № 9. ‒ C. 1113-9.
92. Rinner C., Tschandl P., Sinz C., Kittler H. Long-term evaluation of the efficacy of digital dermatoscopy monitoring at a tertiary referral center // J Dtsch Dermatol Ges. ‒ 2017. ‒ T. 15, № 5. ‒ C. 517-522.
93. Robinson J. K., Nickoloff B. J. Digital epiluminescence microscopy monitoring of high-risk patients // Arch Dermatol. ‒ 2004. ‒ T. 140, № 1. ‒ C. 49-56.
94. Argenziano G., Agozzino M., Bonifazi E., Broganelli P., Brunetti B., Ferrara G., Fulgione E., Garrone A., Zalaudek I. Natural evolution of Spitz nevi // Dermatology. ‒ 2011. ‒ T. 222, № 3. ‒ C. 256-60.
95. Berk-Krauss J., Polsky D., Stein J. A. Mole Mapping for Management of Pigmented Skin Lesions // Dermatol Clin. ‒ 2017. ‒ T. 35, № 4. ‒ C. 439-445.
96. Truong A., Strazzulla L., March J., Boucher K. M., Nelson K. C., Kim C. C., Grossman D. Reduction in nevus biopsies in patients monitored by total body photography // J Am Acad Dermatol. ‒ 2016. ‒ T. 75, № 1. ‒ C. 135-143 e5.
97. Inskip M., Magee J., Weedon D., Rosendahl C. When algorithms falter: a case report of a very small melanoma excised due to the dermatoscopic "ugly duckling" sign // Dermatol Pract Concept. ‒ 2013. ‒ T. 3, № 2. ‒ C. 59-62.
98. Akay B. N., Okcu Heper A., Clark S., Erdem C., Rosendahl C. O., Kittler H. Dermatoscopy of a melanoma less than one millimeter in diameter // Int J Dermatol. ‒ 2017. ‒ T. 56, № 12. ‒ C. 1498-1499.
99. Bafounta M. L., Beauchet A., Chagnon S., Saiag P. Ultrasonography or palpation for detection of melanoma nodal invasion: a meta-analysis // Lancet Oncol. ‒ 2004. ‒ T. 5, № 11. ‒ C. 673-80.
100. Farberg A. S., Rigel D. S. A comparison of current practice patterns of US dermatologists versus published guidelines for the biopsy, initial management, and follow up of patients with primary cutaneous melanoma // J Am Acad Dermatol. ‒ 2016. ‒ T. 75, № 6. ‒ C. 1193-1197 e1.
101. Weinstock M. A., Lott J. P., Wang Q., Titus L. J., Onega T., Nelson H. D., Pearson L., Piepkorn M., Elmore J. G., Tosteson A. N. Skin Biopsy Utilization and Melanoma Incidence among Medicare Beneficiaries // Br J Dermatol. ‒ 2016.10.1111/bjd.15077.
102. Rayess H. M., Gupta A., Svider P. F., Raza S. N., Shkoukani M., Zuliani G. F., Carron M. A. A critical analysis of melanoma malpractice litigation: Should we biopsy everything? // Laryngoscope. ‒ 2017. ‒ T. 127, № 1. ‒ C. 134-139.
103. Moscarella E., Argenziano G., Moreno C., Piana S., Lallas A., Lombardi M., Longo C., Ferrara G. Intralesional (incision) biopsy for melanoma diagnosis: the rules and the exception to the rules // G Ital Dermatol Venereol. ‒ 2016.
104. Bolshinsky V., Lin M. J., Serpell J., Leung M., Wolfe R., McLean C., Kelly J. W. Frequency of residual melanoma in wide local excision (WLE) specimens after complete excisional biopsy // J Am Acad Dermatol. ‒ 2016. ‒ T. 74, № 1. ‒ C. 102-7.
105. Luk P. P., Vilain R., Crainic O., McCarthy S. W., Thompson J. F., Scolyer R. A. Punch biopsy of melanoma causing tumour cell implantation: another peril of utilising partial biopsies for melanocytic tumours // Australas J Dermatol. ‒ 2015. ‒ T. 56, № 3. ‒ C. 227-31.
106. Soltani-Arabshahi R., Sweeney C., Jones B., Florell S. R., Hu N., Grossman D. Predictive value of biopsy specimens suspicious for melanoma: support for 6-mm criterion in the ABCD rule // J Am Acad Dermatol. ‒ 2015. ‒ T. 72, № 3. ‒ C. 412-8.
107. Mills J. K., White I., Diggs B., Fortino J., Vetto J. T. Effect of biopsy type on outcomes in the treatment of primary cutaneous melanoma // Am J Surg. ‒ 2013. ‒ T. 205, № 5. ‒ C. 585-90; discussion 590.
108. de Lecea M. V., Palomares T., Al Kassam D., Cavia M., Geh J. L., de Llano P., Muniz P., Armesto D., Martinez-Indart L., Alonso-Varona A. Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B // J Eur Acad Dermatol Venereol. ‒ 2016.10.1111/jdv.13968.
109. Nikolin B., Djan I., Trifunovic J., Dugandzija T., Novkovic D., Djan V., Vucinic N. MIA, S100 and LDH as important predictors of overall survival of patients with stage IIb and IIc melanoma // J BUON. ‒ 2016. ‒ T. 21, № 3. ‒ C. 691-7.
110. Wevers K. P., Kruijff S., Speijers M. J., Bastiaannet E., Muller Kobold A. C., Hoekstra H. J. S-100B: a stronger prognostic biomarker than LDH in stage IIIB-C melanoma // Ann Surg Oncol. ‒ 2013. ‒ T. 20, № 8. ‒ C. 2772-9.
111. Egberts F., Kotthoff E. M., Gerdes S., Egberts J. H., Weichenthal M., Hauschild A. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma // Eur J Cancer. ‒ 2012. ‒ T. 48, № 5. ‒ C. 695-702.
112. Egberts F., Momkvist A., Egberts J. H., Kaehler K. C., Hauschild A. Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients // Anticancer Res. ‒ 2010. ‒ T. 30, № 5. ‒ C. 1799-805.
113. Agarwala S. S., Keilholz U., Gilles E., Bedikian A. Y., Wu J., Kay R., Stein C. A., Itri L. M., Suciu S., Eggermont A. M. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951) // Eur J Cancer. ‒ 2009. ‒ T. 45, № 10. ‒ C. 1807-14.